Did Krug et al. find Pfizer Vaccine-Associated Myocarditis/Pericarditis in Adolescents using a Stratified Risk-Benefit Analysis? Yes, overwhelmingly in n=253 persons aged 12-17 years
by Paul Alexander
In boys with prior infection and no comorbidities, even one dose carried more risk than benefit according to international estimates.
SOURCE:
https://onlinelibrary.wiley.com/doi/10.1111/eci.13759
‘Cases of myo/pericarditis (n = 253) included 129 after dose 1 and 124 after dose 2; 86.9% were hospitalized.
Incidence per million after dose two in male patients aged 12–15 and 16–17 was 162.2 and 93.0, respectively. Weighing post-vaccination myo/pericarditis against COVID-19 hospitalization during delta, our risk-benefit analysis suggests that among 12–17-year-olds, two-dose vaccination was uniformly favourable only in nonimmune girls with a comorbidity.
In boys with prior infection and no comorbidities, even one dose carried more risk than benefit according to international estimates.’
So then why did CDC lie in their MMWR reporting?
